Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 7Carcinoma, Renal Cell 6Neoplasm Metastasis 4Carcinoma, Transitional Cell 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Glioblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Basal Cell 2Vulvar Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sjogren's Syndrome 1Seminoma 1Scleroderma, Systemic 1Sarcoma 1Rectal Neoplasms 1

Interventions

Cisplatin 12Gemcitabine 9Specimen Handling 6Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Drug Therapy 5toripalimab 4Platinum 4Nivolumab 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3Radiotherapy 3Immune Checkpoint Inhibitors 3sintilimab 2Ipilimumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tislelizumab 1relatlimab 1pembrolizumab 1olaparib 1fluciclovine F-18 1dehydroftorafur 1cemiplimab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × CTLA-4 Antigen × 30 days × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡